In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy

PulmoPrint is a clinical study at the University Medical Center Groningen (UMCG) that investigates why some patients with unresectable stage III lung cancer don't respond to immunotherapy after chemoradiotherapy. To do this, a small dose of a fluorescently labeled version of the immunotherapy drug durvalumab is given via an intravenous (IV) drip, after which a bronchoscopy is performed to visualize where and how much of the drug reaches the tumor and lymph nodes - before the actual durvalumab treatment starts.

NCT Number	NCT07653438
Lead Sponsor	University Medical Center Groningen
Conditions	Stage III Non-small Cell Lung Cancer, Unresectable Stage III NSCLC
Enrollment	20 participants
Start Date	2026-09-01
Primary Completion	2028-03-01 (estimated)
Study Completion	2031-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-15